What Is the EGFR Exon 19 Deletion in Lung Cancer?

An EGFR exon 19 deletion means a small piece is missing from a gene in the cancer cells, and that gap keeps a growth signal running nonstop. The change happens in the tumor’s DNA and is not something you inherited. It is not passed to children, and family members don’t need testing for it.¹ Because the tumor leans so heavily on that one signal, the signal becomes a target. For most people this is considered favorable news: it opens the door to daily pills that switch the signal off instead of relying on chemotherapy alone. In advanced disease, though, those pills control the cancer rather than cure it, so treatment becomes a long-term plan with next steps ready.

What Is Actually Missing and Why It Drives the Cancer

EGFR is a protein on the surface of cells. Normally it tells a cell to grow only when a signal molecule docks onto it. Genes are read in sections, and the section called exon 19 codes part of the switch’s control area. Removing a short stretch there shortens a loop, which pulls part of the protein into its “on” position and keeps it from flipping off.² The switch then signals constantly, telling cells to keep dividing.³ Some deletion versions can switch on even with no signal molecule present at all.⁴

Because the protein is built from the gene’s instructions, a shortened instruction produces a slightly shorter protein in every cell that carries the change, so the whole tumor shares the same stuck switch. Normal cells elsewhere in the body still have ordinary EGFR, which is part of why pills aimed at the changed version can be tolerated.

The cancer becomes dependent on this one signal, so blocking it can make tumors shrink quickly. This is why the result changes the first treatment choice.

Your report may say “exon 19 deletion,” “ex19del,” or a code like E746_A750del. The code names which building blocks are missing, by position number, and E746_A750del is the most common version. Ask your oncologist which version you have, since it can matter slightly for treatment.

Who Has It and How It Is Found

About half of lung cancers with an EGFR mutation have an exon 19 deletion, in both Asia and Europe.⁵ The next most common is a single-letter change in exon 21 called L858R, found in roughly 30 to 40 percent.⁶ Together these two are called the “classic” EGFR mutations, and both respond to targeted pills.⁷

EGFR mutations are found mostly in adenocarcinoma, the most common type of non-small cell lung cancer.⁸ They are much more common in women and in people who never smoked.⁹ People of Asian descent have higher odds, and in one large study of surgically removed cancers, half of patients had an EGFR mutation.¹⁰ Smokers can still have it, so testing is recommended for everyone with advanced non-squamous lung cancer, and increasingly for earlier-stage cancers too.

Doctors usually test a piece of tumor tissue from the biopsy using a panel that reads many genes at once.¹¹ In one study, a blood test for tumor DNA, often called a liquid biopsy, missed nearly half of key mutations that tissue testing caught in lung adenocarcinoma.¹² So a negative blood test doesn’t rule out an EGFR mutation; ask whether tissue testing was done.

Because a panel reads many cancer-related genes in one run, the same report may list EGFR alongside others such as ALK, ROS1, KRAS, and MET. Finding an EGFR change usually means other major drivers are absent, since these changes mostly occur on their own rather than together. The report may also list changes with no known treatment effect, and your oncologist can say which lines on the page actually matter for you.

Sometimes a biopsy yields too little tumor for a full panel, and the report says “insufficient” or “not evaluable” instead of “negative.” Those are not the same thing. The usual next step is to try another sample or a blood test while tissue options are reviewed. If you see that wording, ask whether repeat testing is planned and how long it would take. Gene results can take one to three weeks, and doctors often wait for them before starting treatment, since starting the right pill first matters more than starting a few days sooner.

The Standard Treatment Targeted Pills

Targeted therapy for this mutation comes as pills called EGFR tyrosine kinase inhibitors, or TKIs. They block the stuck switch from the inside.¹³ The first ones, gefitinib and erlotinib, produced dramatic responses that led to the discovery of these mutations.¹⁴ Exon 19 deletions bind these drugs easily, so the drugs block them effectively.¹⁵

Osimertinib (Tagrisso) is a newer, third-generation pill that crosses into the brain better than older EGFR pills.¹⁶ That means it can control cancer that has spread to the brain, including the lining around it.¹⁷ In stage III cancer after chemoradiation, about 9 percent on osimertinib had brain progression within a year versus 36 percent without it.¹⁸

It also helps earlier-stage disease. After surgery for stage IB to IIIA cancer, taking osimertinib for 3 years keeps cancer away much longer.¹⁹ At 4 years, 73 percent on osimertinib were alive and cancer-free versus 38 percent on placebo.²⁰

Immunotherapy drugs that help many lung cancers work poorly in EGFR-mutated cancer.²¹ The active EGFR signal helps the tumor hide from and suppress the immune system.²² So targeted pills, not immunotherapy, are usually the first choice. Chemotherapy attacks fast-dividing cells in general, while the pill targets a weakness specific to the cancer. Some people with advanced disease are offered chemotherapy together with a targeted pill at the start, and your oncologist can explain whether that applies to your stage and health. Choosing a pill first doesn’t close off chemotherapy, which stays available later.

The pill is taken once a day at home, and treatment continues as long as it keeps working. Scans every few months check whether it still is.

Treatment begins with a prescription, often through a specialty pharmacy, so ask your team early how and when the first supply will arrive. Many people notice cough or breathing easing within the first weeks if the tumor responds, though this varies and scans are the real measure. Early side effects such as rash or loose stools often appear in those same weeks, so that is when to stay in close contact with your team.

How Exon 19 Compares With L858R

Across many studies, people with exon 19 deletions stayed controlled on targeted pills longer and lived longer than those with the other common EGFR change.²³ Their tumors were also about twice as likely to shrink noticeably.²⁴ In one brain-metastasis study, brain control lasted a median 31.8 months with exon 19 versus 8.3 months with L858R.²⁵

The two mutations change the switch in different ways, so the drugs fit and block them with different efficiency. That shape difference helps explain why exon 19 deletions respond a bit better, but researchers do not fully understand all the reasons.

Not all exon 19 deletions are equal. On osimertinib, the common E746_A750del version stayed controlled a median 21.3 months versus 11.7 months for the L747_A750>P version.²⁶ Some versions grip the cell’s fuel more tightly, which makes them harder to block.²⁷ Deletions starting at position E746 were linked to longer survival than those starting at L747.²⁸ These figures are medians from groups, not predictions for one person; many people do far better.

The comparison is between two treatable mutations, not between good and bad. Many people with L858R also do well for a long time on targeted pills, with access to the same drugs.

When the Pills Stop Working

Tumors contain billions of cells, and a few may already carry changes that let them survive the pill. Once the sensitive cells are cleared, these cells grow. Resistance is the cancer evolving under treatment, not the drug wearing out or the patient doing something wrong. Because the process is predictable, doctors plan for it from the start.

Progression is usually seen on a routine scan before symptoms. Sometimes only one spot grows, and it can be treated with radiation while the pill continues.

On older EGFR pills, about half to 60 percent of resistant cancers develop a second EGFR change called T790M.²⁹ The common exon 19 version is especially likely to develop it.³⁰ T790M alters the pocket where older pills bind, so they no longer fit well. Osimertinib was designed to bind despite it. Finding T790M after older pills is one of the clearest examples of a biopsy changing the next treatment.

After osimertinib, the most common new EGFR change is C797S, which strongly favors exon 19 tumors.³¹ It changes the exact spot where osimertinib attaches, so the drug can no longer lock on. Whether it is treatable depends partly on whether it appears on the same copy of the gene as other changes, which specialist labs can sometimes work out. Because it is a changed EGFR rather than a new route, trials of fourth-generation EGFR drugs are aimed at it.

About 15 percent of resistance to osimertinib comes from MET amplification, where the cancer uses a backup growth route.³² The cancer makes many extra copies of the MET gene, which gives growth signals a side road around the blocked switch. Treatment can then add a drug aimed at MET alongside the EGFR pill. In 4 to 15 percent of cases the tumor transforms into small cell lung cancer, which needs different treatment.³³

Because each cause needs a different treatment, doctors test the tumor again when it grows. Ask whether a new tissue biopsy or blood test for tumor DNA is planned.

Treatments After Osimertinib

Amivantamab is an antibody that blocks both EGFR and MET. Combined with the pill lazertinib, it shrank tumors in about a third of people after osimertinib.³⁴ After both osimertinib and chemotherapy, about 35 percent responded, with responses lasting a median 8.3 months.³⁵ Chemotherapy also remains a standard option at this stage.

Amivantamab is given by infusion into a vein, while lazertinib is a daily pill. The antibody blocks EGFR and MET from outside the cell and the pill blocks EGFR from inside. Infusion visits are scheduled at your treatment center, so it is more time-intensive than pills alone.

Amivantamab can cause reactions during the first infusion, such as chills or breathing trouble, so teams give medicines beforehand and watch closely. Skin problems, nail problems and swelling are common, and blood clots are a recognized risk, so ask what warning signs to report. Your team may adjust the schedule or add supportive medicines to help you stay on treatment.

Chemotherapy usually means a platinum drug with a partner drug, given by infusion in cycles with rest between them. It is often chosen when no targetable resistance change is found or when the cancer is growing fast.

Many new drugs target specific resistance changes, and your rebiopsy result may qualify you for a trial. Ask your team or search trial registries early.

Side Effects of EGFR Pills

EGFR pills are generally gentler than chemotherapy.³⁶ They do commonly cause an acne-like rash and diarrhea.³⁷ Mouth sores and painful inflammation around nails are common too.³⁸ Eye problems can occur, and rarely, lung inflammation.³⁹

The rash looks like acne on the face, scalp, chest and upper back, and it often appears in the first weeks of treatment. It differs from true acne because there are no blackheads, and acne products can dry or irritate the skin. It often settles into dry, itchy skin, so report a rash that is widespread, painful, or looks infected.

Mild diarrhea is common, and a plan for it should be in place before you start. Drink fluids steadily, since dehydration is the main danger. Call your team if it is severe, lasts more than a day or two despite treatment, or comes with fever, dizziness, or blood.

Treating side effects early helps people stay on the full dose.⁴⁰ Use gentle moisturizers, avoid harsh soaps, and protect your skin from the sun. Keep loperamide on hand if advised. Don’t stop the pill yourself; doctors can adjust the dose. Report new breathlessness or cough right away.